Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).

NCT04842747 is registered in ClinicalTrials.gov with Veru Inc. as lead sponsor.

NCT NCT04842747
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04842747 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).
Lead sponsor
Veru Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 18, 2021
Completion date
July 6, 2022
Enrollment
204 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov infection